Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edaravone-dexborneol (Xianbixin) for idiopathic normal pressure hydrocephalus with metabolomics mechanism study
ChiCTR2600125153Phase 4Recruiting
- Sponsor
- Tianjin Huanhu Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of edaravone dexborneol in Idiopathic Normal Pressure Hydrocephalus (NPH) (4 arms), sponsored by Tianjin Huanhu Hospital. Primary endpoint: Idiopathic normal pressure hydrocephalus (iNPH) scale score at day 14. Started May 2026; status: recruiting.
02
Drugs
edaravone dexborneol
03
Conditions
Idiopathic Normal Pressure Hydrocephalus (NPH)
Beyond the preview
Go deeper on ChiCTR2600125153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125153.